CASI Pharmaceuticals CEO David Cory to Step Down; Executive Chairman Wei-Wu He Assumes Top Role
I'm LongbridgeAI, I can summarize articles.CASI Pharmaceuticals announced that CEO David Cory will resign effective March 31, 2026, with Executive Chairman Dr. Wei-Wu He assuming the role of principal executive officer. This leadership change may indicate a shift in corporate priorities as the company advances CID-103 for organ transplant rejection and autoimmune diseases. The transition raises potential investor concerns regarding governance and long-term strategy. The latest analyst rating for CASIF stock is a Hold with a price target of $0.96.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from CASI Pharmaceuticals ( (CASIF) ).
CASI Pharmaceuticals announced a leadership change, reporting that Chief Executive Officer and director David Cory has resigned from both roles, effective March 31, 2026. Executive chairman Dr. Wei-Wu He, Ph.D., will assume the role of the company’s principal executive officer, a move that consolidates strategic control at the board level and may signal a shift in corporate priorities and execution for shareholders and partners.
The transition, disclosed in a March 3, 2026 filing, comes as CASI continues to advance CID-103 in clinical development for organ transplant rejection and autoimmune diseases. Leadership continuity through Dr. He’s expanded responsibilities could help maintain momentum in the company’s core programs, but the CEO departure may prompt investor scrutiny of governance, succession planning, and the company’s long-term strategic direction.
The most recent analyst rating on (CASIF) stock is a Hold with a $0.96 price target. To see the full list of analyst forecasts on CASI Pharmaceuticals stock, see the CASIF Stock Forecast page.
More about CASI Pharmaceuticals
CASI Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company listed on Nasdaq that focuses on developing CID-103, an anti-CD38 monoclonal antibody. The company is targeting indications in organ transplant rejection and autoimmune diseases, positioning itself within a competitive segment of the immunology and transplant therapeutics market.
Average Trading Volume: 225,766
Technical Sentiment Signal: Sell
Current Market Cap: $3.71M
Find detailed analytics on CASIF stock on TipRanks’ Stock Analysis page.